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Infection can negatively impact brain functions. Here, Duan et al. (2018) show that specific PDGFRb-expressing cell subtypes of the neurovascular unit release the chemokine CCL2 rapidly after systemic infection, leading to increased neural excitability.
When infection spreads in the body, organs suffer. In some circumstances, brain inflammation may develop from infection and affect neuronal functions (Klein et al., 2017) . Understanding of the precise sequence of cellular and molecular events that occur in the brain after infection could guide the development of treatments to limit brain damage. Glial cells, mainly microglia and astrocytes, are key players in neuroinflammation. The resident immune cells of the nervous system, microglia are considered first responders. Microglia have motile processes that constantly survey the parenchyma and physically respond to local injury within minutes (Davalos et al., 2005; Nimmerjahn et al., 2005) . Both microglia and astrocytes contribute to acute and chronic inflammation by proliferating and releasing immune factors, such as cytokines and chemokines. For example, in response to systemic lipopolysaccharide (LPS) administration to model bacterial infection, microglia become activated with delayed directed process motility and repress hippocampal neurogenesis (Gyoneva et al., 2014; Monje et al., 2003) . Systemic infection may compromise the integrity of the blood-brain barrier (BBB), which is regulated by endothelial cell tight junctions, astrocytic endfeet, microglia, and pericytes that together restrict the passage of plasma proteins and cells into the brain. In most studies, the effects of infection on cells that control BBB integrity are assessed at time points 24 hr and longer after initial infection.
In this issue of Neuron, Duan et al. (2018) shed new light on the very early triggers of neuroinflammation by investigating the molecular events that occur in the brain 2 hr following systemic bacterial or viral infection. Using a multi-pronged experimental approach including infection models in mice, single-cell RNA sequencing (scRNA-seq), histology, slice electrophysiology, behavior, and in vitro cell culture studies, the authors showed that two subtypes of perivascular cells expressing platelet-derived growth factor receptor beta (PDGFRb) were the predominant early source of the CC chemokine ligand 2 (CCL2, also referred to as monocyte chemotactic protein-1, MCP1) (Duan et al., 2018) . The authors find that PDGFRb + cell-secreted CCL2 increased excitatory synaptic transmission by acting on neurons ( Figure 1 ). This work provides in vivo demonstration of PDGFRb + cells as early neuroinflammatory mediators and reveals a mechanism by which systemic infection can impact neuronal activity. Duan et al. (2018) first assessed the hippocampal transcript and protein levels of cytokines and chemokines considered the ''usual suspects'' in neuroinflammation at 2 hr post-intraperitoneal injection of bacterial or viral mimetics into 2-week-old mice. The authors determined that CCL2 was the most highly induced chemokine in the hippocampus 2 hr after infection, and made the unanticipated discovery that Ccl2 mRNA was mainly upregulated in PDGFRb + cells, but not in endothelial cells, microglia, or astrocytes. The authors performed scRNA-seq to further dissect the transcriptional profile and identity of Ccl2-expressing cells after LPS injection. The cell populations with the highest Ccl2 expression were collagen type I, alpha 1 (Col1a1)-expressing cells, regulator of G protein signaling 5 (Rgs5)-expressing cells, microglia, and astrocytes. Microglia expressed Ccl2 at similar levels in both control and LPS treatment. LPS increased Ccl2 expression in astrocytes, but at lower levels than Pdgfrb-expressing cells. By crossreferencing previous profiling studies with their own scRNA-seq and histological verification, Duan et al. (2018) determined that CCL2 was mainly expressed by Col1a1 + Pdgfrb + cells, a perivascular fibroblast-like cell that lies at the meninges and large blood vessels, and Rgs5 + Pdgfrb + cells, a population of cells lining small vessels that include pericytes.
Further evidence that PDGFRb + cells were the major contributors of CCL2 at 2 hr post-infection was obtained from conditional knockout mouse studies. Specific deletion of Ccl2 in Pdgfrb + cells, but not in Tie2 + endothelial cells, reduced total hippocampal Ccl2 gene expression and CCL2 protein levels after infection. Cell-specific deletion of Ccl2 in PDGFRb + cells also rescued LPSinduced prolonged immobility during the mouse tail suspension test, a proposed model for sickness behavior. What is striking about these findings is that PDGFRb + cells, which include pericytes and other perivascular fibroblast-like cells, are generally not considered as first responders in neuroinflammation. Indeed, the described roles of pericytes include primarily the establishment and regulation of the BBB and other cerebrovascular functions (Sweeney et al., 2016) . While pericytes express pathogen-associated molecular pattern (PAMP) receptors, release cytokines, and present antigens (Rustenhoven et al., 2017) , data supporting a potential role for pericytes in neuroinflammation come mostly from in vitro studies. Now, Duan et al. (2018) provide in vivo functional evidence that two subpopulations of PDGFRb + cells, namely the Rgs5 + Pdgfrb + pericytes along with a Col1a1 + Pdgfrb + perivascular fibroblast-like cell type, rapidly respond to systemic infection by producing the bulk of CCL2.
Although previous studies have demonstrated that CCL2 signaling can influence neuronal excitability (Cerri et al., 2017) , Duan et al. (2018) use a robust set of in vitro and ex vivo experimental approaches, including whole-cell recordings in acute postnatal brain slices, to determine the effect of PDGFRb + cell-derived CCL2 on neuronal activity. They find that CCL2 intensified AMPA receptor-mediated evoked excitatory postsynaptic potentials (EPSCs) accompanied by an increase in total synaptic charge. Notably, the paired-pulse ratio as a measure of presynaptic release probability and GABAergic inhibitory neurotransmission were not affected by CCL2, suggesting that CCL2 specifically increased postsynaptic neuronal excitability. Using mice deficient for the major CCL2 receptor C-C chemokine receptor type 2 (CCR2) or decreasing CCR2 in neurons by RNAi showed that neuronal CCR2 is required for CCL2 to increase excitatory neurotransmission. Importantly, CCL2 derived from cultured human brain vascular pericytes stimulated with LPS or the viral mimetic Poly(I:C) was sufficient to increase total neuronal excitability when applied to slices. In acute brain slice recordings, LPS-injected Ccl2 knockout mice or mice lacking Ccl2 specifically in PDGFRb + cells had lower mEPSC frequencies than LPS-injected littermate controls. Since these effects were observed in pyramidal cells of the primary somatosensory cortex, hippocampal CA1 and CA3 regions, and granule cells of the dentate gyrus, PDGFRb + cells may mediate inflammation-induced aberrant neuronal activity via CCL2 on a brain-wide scale. Given the importance of AMPA receptor signaling in memory and learning, could CCL2 released by PDGFRb + cells affect cognitive functions? Furthermore, are any of these mechanisms altered with age? The authors show that their major findings can be recapitulated in adult mice around 2 and 7 months of age, but whether these effects occur in aged mice remains to be tested. Future studies are warranted to reveal whether a boost in excitatory neurotransmission by PDGFRb + cell-derived CCL2 drives changes to neuronal circuits in vivo.
Another important consideration raised by Duan et al. (2018) concerns the relative contributions of microglia and PDGFRb + cells to neuroinflammation during infection. While Duan et al. (2018) show that PDGFRb + cell subtypes were the largest early source of CCL2, microglia also produce CCL2 and other immune signaling molecules, although perhaps at a timescale longer than 2 hr post-infection. Is early CCL2 release by PDGFRb + cells a transient response or is it also required for chronic inflammatory responses by microglia and astrocytes? Are the effects of early CCL2 release additive or synergistic to microglial CCL2 or release of other immunomodulators during chronic inflammation? The authors provide transcriptional and protein evidence that PDGFRb + cells were perhaps the quickest responders to infection. At 2 and 6 hr post-infection, Duan et al. (2018) did not observe microgliosis and astrogliosis in the hippocampus. However, a previous in vivo twophoton imaging study demonstrated that microglial process motility dynamics are altered 48 hr after systemic infection (Gyoneva et al., 2014) . Is it possible not only that microglial process motility is affected, but also that pericytes and other perivascular cells modify their physical dynamics around blood vessels in response to infection? Finally, the authors suggest that the BBB is not open at 2 hr post-LPS injection because of negligible leakage of the serum albumin-binding dye Evans blue in the brain at this time point. To unequivocally demonstrate that the BBB is not altered, more detailed examination, including assessment of tight junctions and leakage of other plasma proteins, is needed (Petersen et al., 2018) . Indeed, microglia and pericytes are cell targets of the plasma protein fibrinogen (reviewed in Petersen et al., 2018) . Fibrinogen induces Ccl2 expression in microglia and is a trigger for rapid and sustained microglial responses (Petersen et al., 2018) . A provocative study has shown an interaction between microglia and pericytes in disease by identifying that RGS5 + pericytes can assume a microglial-like phenotype after ischemic stroke (Rustenhoven et al., 2017) . These studies together with Duan et al. (2018) provide a rationale for future investigation of the crosstalk between microglia, pericytes, neurons, and the BBB after systemic infection, cerebrovascular damage, and chronic inflammation.
In summary, the study by Duan et al. (2018) describes a new role for PDGFRb + cells as early neuroinflammatory mediators that can influence neural excitability after infection. Transcriptional profiling of subpopulations of cells at the neurovascular unit by single-cell analysis has the potential to change the way we think about the cellular mechanisms that regulate the interaction between the brain and the periphery. Determining the types of resident brain cells that are causally involved in neuroinflammation will expand our understanding of how systemic infection alters the bidirectional crosstalk between cells of the neurovascular unit to modulate brain functions. Future research should examine whether similar brain-immune communication pathways control neuronal activity in non-infectious inflammatory conditions, such as in autoimmune or neurodegenerative diseases with chronic brain inflammation.
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